SCHEMBL6036629

SCHEMBL6036629

O=C(O)C1(CS(=O)(=O)N2CCC(Oc3cccc(C(F)(F)F)c3)CC2)CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
MMP13 P45452 5/20 0.49
MMP12 P39900 2/20 0.47
EPHX2 P34913 1/20 0.46
AURKA O14965 1/20 0.45
AURKB Q96GD4 1/20 0.45
INCENP Q9NQS7 1/20 0.45
MMP14 P50281 3/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
LMNA P02545 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
MGLL Q99685 1/20 0.40
ABHD6 Q9BV23 1/20 0.40
FFAR1 O14842 2/20 0.40
NR1I2 O75469 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6036512 0.90 MMP2 (0.51) TP53MEN1KMT2AMMP13EPHX2
SCHEMBL6035783 0.90 MMP13 (0.58) MMP13MMP12EPHX2MMP14MMP2
SCHEMBL6948792 0.81 MMP13 (0.56) MMP13MMP12MMP14MMP2MMP3
SCHEMBL6036011 0.80 MMP13 (0.55) TP53MMP13MMP12EPHX2MMP14
SCHEMBL6035791 0.80 MMP13 (0.53) MMP13MMP12MMP14MMP2MMP3
SCHEMBL6943119 0.78 MMP13 (0.52) MMP13MMP12MMP14MMP2RORC
SCHEMBL9903075 0.73 EPHX2 (0.65) TP53MEN1KMT2AEPHX2SCN10A
SCHEMBL6097841 0.73 MMP13 (0.49) TP53MEN1KMT2AMMP13MMP12
SCHEMBL29703881 0.72 TP53 (0.44) TP53MEN1KMT2AMMP13EPHX2
Hydrochloric Acid SCHEMBL29705662 0.72 TP53 (0.43) TP53MEN1KMT2AMMP13EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7015234-B2 Hydroxamic acid derivatives CELLTECH R & D LIMITED (GB) 2006-03-21 US disclosed
EP-1414812-B1 HYDROXAMIC ACID DERIVATIVES CELLTECH R&D LTD (GB) 2006-02-22 EP disclosed
US-20040192733-A1 Hydroxamic acid derivatives UCB PHARMA S.A. (BE) 2004-09-30 US disclosed
EP-1414812-A1 HYDROXAMIC ACID DERIVATIVES Celltech R & D Limited (GB) 2004-05-06 EP disclosed
WO-2003014101-A1 HYDROXAMIC ACID DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192733-A1 Hydroxamic acid derivatives MMP1, MMP3, MMP13 TP53 4696/4885MEN1 2905/4885KMT2A 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.